药物信息为Morphine Sulfate Extended-Release TabletsCII15 mg, 30 mg, 60 mg, 100 mg* and 200 mg*Rx only (Mallinckrodt Inc.): DESCRIPTION
- DESCRIPTION
- CLINICAL PHARMACOLOGY
- Central Nervous System
- Gastrointestinal Tract and Other Smooth Muscle
- Cardiovascular System
- Endocrine System
- Immune System
- Pharmacodynamics
- Plasma Level - Analgesia Relationships
- Concentration - Adverse Experience Relationships
- PHARMACOKINETICS AND METABOLISM
- INDICATIONS AND USAGE
- CONTRAINDICATIONS
- WARNINGS
- Misuse, Abuse and Diversion of Opioids
- Interactions with Alcohol and Drugs of Abuse
- Drug Abuse and Addiction
- Respiratory Depression
- Head Injury and Increased Intracranial Pressure
- Hypotensive Effect
- Interactions with Other CNS Depressants
- Other
- PRECAUTIONS
- ADVERSE REACTIONS
- Most Frequently Observed
- Less Frequently Observed Reactions
- OVERDOSAGE
- DOSAGE AND ADMINISTRATION
- Conversion from Conventional Oral Morphine to Morphine Sulfate Extended-Release Tablets
- Conversion from Parenteral Morphine or Other Opioids (Parenteral or Oral) to Morphine Sulfate Extended-Release Tablets
- Use of Morphine Sulfate Extended-Release Tablets as the First Opioid Analgesic
- Considerations in the Adjustment of Dosing Regimens
- Special Instructions for Morphine Sulfate Extended-Release 100 mg and 200 mg Tablets (For use in opioid-tolerant patients only.)
- Supplemental Analgesia
- Continuation of Therapy
- Cessation of Therapy
- Conversion from Morphine Sulfate Extended-Release Tablets to Parenteral Opioids
- SAFETY AND HANDLING
- HOW SUPPLIED
- PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 15 mg
- PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 30 mg
- PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 60 mg
- PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 100 mg
- PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 200 mg
- 外部链接相关的Morphine Sulfate Extended-Release TabletsCII15 mg, 30 mg, 60 mg, 100 mg* and 200 mg*Rx only (Mallinckrodt Inc.)
Morphine Sulfate Extended-Release Tablets are supplied in tablet form for oral administration.Chemically, morphine sulfate is 7,8-didehydro-4,5a-epoxy-17-methylmorphinan-3,6a-diol sulfate (2:1) (salt) pentahydrate and has the following structural formula:

Morphine sulfate extended-release tablets are opiate analgesics supplied in 15, 30, 60, 100* and 200* mg tablet strengths. The tablet strengths describe the amount of morphine per tablet as the pentahydrated sulfate salt (morphine sulfate USP).All strengths contain the following inactive ingredients: hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, silicone dioxide, titanium dioxide, and triacetine. The 15 mg tablets also contain: polyethylene glycol, polydextrose, and FD&C Blue No. 2. The 30 mg tablets also contain: polyethylene glycol, polydextrose, FD&C Blue No. 2, and D&C Red No. 7. The 60 mg tablets also contain: polyethylene glycol, polydextrose, FD&C Yellow No. 6, and iron oxide red. The 100 mg* tablets also contain: iron oxide black. The 200 mg* tablets also contain: polyethylene glycol, FD&C Blue No. 1, and D&C Yellow No. 10 Lake.*100 mg and 200 mg ARE FOR USE IN OPIOID-TOLERANT PATIENTS ONLY.
- Drug Information Provided by National Library of Medicine (NLM).
